Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   

COVID-19: Daily Top 10 Papers


  Free Subscription

Articles published in J Cardiovasc Pharmacol

Retrieve available abstracts of 25 articles:
HTML format

Single Articles

    November 2021
  1. ZHENG RJ, Wang Y, Tang JN, Duan JY, et al
    Association of SGLT2 inhibitors with risk of atrial fibrillation and stroke in patients with and without type 2 diabetes: a systemic review and meta-analysis of randomized controlled trials.
    J Cardiovasc Pharmacol. 2021 Nov 22. pii: 00005344-900000000-98109.
    PubMed     Abstract available

    Atrial fibrillation induced by anticancer drugs and underling mechanisms.
    J Cardiovasc Pharmacol. 2021 Nov 17. pii: 00005344-900000000-98110.
    PubMed     Abstract available

  3. HIJAZI Y, Karkabi B, Feldman M, Malca B, et al
    Bridging care transition after hospitalization for atrial fibrillation and coronary interventions.
    J Cardiovasc Pharmacol. 2021 Nov 16. pii: 00005344-900000000-98113.
    PubMed     Abstract available

    October 2021
  4. LO CT, Niu F, Fredriks DA, Hui RL, et al
    Evaluation of the effectiveness and safety of Direct Oral Anticoagulants in Elderly Patients with Non-Valvular Atrial Fibrillation who are not Candidates for Warfarin in real world setting.
    J Cardiovasc Pharmacol. 2021 Oct 26. pii: 00005344-900000000-98121.
    PubMed     Abstract available

    August 2021

  5. Efficacy and Safety of Non-Vitamin K Antagonist Oral Anticoagulants in Patients With Atrial Fibrillation and Chronic Kidney Disease Stage G4: A Single-Center Experience: Erratum.
    J Cardiovasc Pharmacol. 2021;78:330.

  6. ZHANG M, Wang H, Bie M, Wang X, et al
    Caveolin-1 Deficiency Induces Atrial Fibrosis and Increases Susceptibility to Atrial Fibrillation by the STAT3 Signaling Pathway.
    J Cardiovasc Pharmacol. 2021;78:175-183.
    PubMed     Abstract available

    June 2021
  7. CHARAFEDDINE K, Zakka P, Dargham BB, Abdulhai F, et al
    Potential Biomarkers in Atrial Fibrillation: Insight into their Clinical Significance.
    J Cardiovasc Pharmacol. 2021 Jun 25. pii: 00005344-900000000-98188.
    PubMed     Abstract available

  8. SKORNOVA I, Samos M, Bolek T, Kamenistakova A, et al
    Direct oral anticoagulants plasma levels in atrial fibrillation patients at the time of bleeding: a pilot prospective study.
    J Cardiovasc Pharmacol. 2021 Jun 25. pii: 00005344-900000000-98186.
    PubMed     Abstract available

    March 2021
  9. HEIDEMANN J, Tanislav C, Kostev K
    (Absence of) Association Between Non-Vitamin K Antagonist Oral Anticoagulant Therapy and Urinary Tract Infection in Patients with Atrial Fibrillation.
    J Cardiovasc Pharmacol. 2021 Mar 12. pii: 00005344-900000000-98230.
    PubMed     Abstract available

    December 2020
  10. CORDERO A, Ferreiro JL, Bertomeu-Gonzalez V, Rodriguez-Manero M, et al
    Direct oral anticoagulants vs. vitamin K antagonist after percutaneous coronary interventions in patients with atrial fibrillation: a metanalysis of cardiac ischemic events.
    J Cardiovasc Pharmacol. 2020;Publish Ahead of Print.
    PubMed     Abstract available

  11. HELENIAK Z, Papuga-Szela E, Krzysztof P, Anetta U, et al
    Efficacy and Safety of Non-Vitamin K Antagonist Oral Anticoagulants in Patients With Atrial Fibrillation and Chronic Kidney Disease Stage G4: A Single-Center Experience.
    J Cardiovasc Pharmacol. 2020;76:671-677.
    PubMed     Abstract available

    November 2020
  12. RIGOPOULOS AG, Kalogeropoulos AS, Tsoporis JN, Sakadakis EA, et al
    Heat shock protein 70 is associated with cardioversion outcome and recurrence of symptomatic recent onset atrial fibrillation in hypertensive patients.
    J Cardiovasc Pharmacol. 2020 Nov 24. doi: 10.1097/FJC.0000000000000962.
    PubMed     Abstract available

  13. NORDBECK P, Hu K
    The trend is your friend: DOACs as standard anticoagulants for patients with atrial fibrillation undergoing percutaneous coronary interventions.
    J Cardiovasc Pharmacol. 2020 Nov 3. doi: 10.1097/FJC.0000000000000950.

    Investigational Anti-Atrial Fibrillation Pharmacology and Mechanisms by Which Antiarrhythmics Terminate the Arrhythmia: Where Are We in 2020?
    J Cardiovasc Pharmacol. 2020;76:492-505.
    PubMed     Abstract available

    October 2020
  15. HENRY M, Wosnitza M, Thate-Waschke IM, Bauersachs R, et al
    A Country-Based Comparison of Atrial Fibrillation Patient Preferences for Oral Anticoagulation: An Evaluation of Discrete Choice Experiments in five different Countries.
    J Cardiovasc Pharmacol. 2020 Oct 30. doi: 10.1097/FJC.0000000000000936.
    PubMed     Abstract available

  16. LEE ZX, Ang E, Lim XT, Arain SJ, et al
    Association of Risk of Dementia with Direct Oral Anticoagulants versus Warfarin use in Patients with Non-valvular Atrial Fibrillation: A Systematic Review and Meta-analysis.
    J Cardiovasc Pharmacol. 2020 Oct 22. doi: 10.1097/FJC.0000000000000925.
    PubMed     Abstract available

  17. PATTI G, Haas S
    Non-vitamin K antagonist oral anticoagulants and factors influencing the ischaemic and bleeding risk in elderly patients with atrial fibrillation: a review of current evidence.
    J Cardiovasc Pharmacol. 2020 Oct 9. doi: 10.1097/FJC.0000000000000927.
    PubMed     Abstract available

    August 2020
  18. NORDBECK P, Hu K
    Choosing Wisely: Cardiovascular Drug Therapy in the Era of COVID-19.
    J Cardiovasc Pharmacol. 2020;76:123-124.

    July 2020
  19. CHU Y, Yang Q, Ren L, Yu S, et al
    Late sodium current in atrial cardiomyocytes contributes to the induced and spontaneous atrial fibrillation in rabbit hearts.
    J Cardiovasc Pharmacol. 2020 Jul 10. doi: 10.1097/FJC.0000000000000883.
    PubMed     Abstract available

  20. JIA K, Dai Y, Liu A, Li X, et al
    The senolytic agent navitoclax inhibits angiotensin II-induced heart failure in mice Navitoclax inhibits heart failure.
    J Cardiovasc Pharmacol. 2020 Jul 10. doi: 10.1097/FJC.0000000000000878.
    PubMed     Abstract available

    May 2020
  21. BURASHNIKOV A, Barajas-Martinez H, Hu D, Robinson VM, et al
    The SK Channel Inhibitors NS8593 and UCL1684 Prevent the Development of Atrial Fibrillation via Atrial-selective Inhibition of Sodium Channel Activity.
    J Cardiovasc Pharmacol. 2020 May 20. doi: 10.1097/FJC.0000000000000855.
    PubMed     Abstract available

  22. RUSSO V, Rago A, Carbone A, Bottino R, et al
    Atrial Fibrillation in COVID-19: From epidemiological association to pharmacological implications.
    J Cardiovasc Pharmacol. 2020 May 18. doi: 10.1097/FJC.0000000000000854.
    PubMed     Abstract available

    March 2020
  23. MA W, Guo X, Wang Q, Sun G, et al
    Systematic Review and Meta-analysis Appraising Efficacy and Safety of Vernakalant for Cardioversion of Recent-onset Atrial Fibrillation.
    J Cardiovasc Pharmacol. 2020 Mar 26. doi: 10.1097/FJC.0000000000000832.
    PubMed     Abstract available

    January 2020
  24. CHOU CC, Lee HL, Huang YC, Wo HT, et al
    Single Bolus Rosuvastatin Accelerates Calcium Uptake and Attenuates Conduction Inhomogeneity in Failing Rabbit Hearts With Regional Ischemia-Reperfusion Injury.
    J Cardiovasc Pharmacol. 2020;75:64-74.
    PubMed     Abstract available

  25. HENDRICKS AK, Nei SD, Greason KL, Scott RA, et al
    Direct Oral Anticoagulant Use After Transcatheter Aortic Valve Replacement: A Case Series.
    J Cardiovasc Pharmacol. 2020;75:41-44.
    PubMed     Abstract available

Thank you for your interest in scientific medicine.

AMEDEO Arrhythmias is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.